Can I Take Folate with Farxiga (Dapagliflozin)?

What Is the Interaction Between Folate and Farxiga?

No pharmacokinetic interaction between folate and dapagliflozin appears in the FDA label for Farxiga, the prescribing information reviewed during the DECLARE-TIMI 58 trial program, or in published interaction databases. Dapagliflozin is metabolized primarily via UGT1A9 glucuronidation in the liver and intestinal wall, a pathway that folate does not inhibit or induce at physiological concentrations [1].

How Dapagliflozin Is Metabolized

Dapagliflozin undergoes O-glucuronidation to its inactive metabolite dapagliflozin 3-O-glucuronide. The UGT1A9 enzyme responsible for this step is not meaningfully affected by B-vitamin supplementation. The FDA label identifies rifampin as a relevant inducer of UGT1A9 activity, but no folate-mediated induction has been reported [1].

Peak dapagliflozin plasma concentration occurs at roughly 1 to 2 hours post-dose. Its terminal half-life is approximately 12.9 hours. Neither of these pharmacokinetic parameters is altered by concurrent B9 supplementation based on currently available evidence.

How Folate Is Absorbed and Processed

Dietary folate and supplemental folic acid enter a separate metabolic pathway. Folic acid is reduced to dihydrofolate and then to tetrahydrofolate (THF) by the enzyme dihydrofolate reductase (DHFR). THF is subsequently methylated to 5-methyltetrahydrofolate (5-MTHF) by methylenetetrahydrofolate reductase (MTHFR). This pathway operates independently of SGLT2 inhibition [2].

Because folate absorption occurs in the proximal jejunum via proton-coupled folate transporter (PCFT/SLC46A1) and reduced folate carrier (RFC/SLC19A1), and dapagliflozin acts on SGLT2 receptors in the renal proximal tubule, the two compounds do not compete for the same transporter systems [2, 3].

Does Dapagliflozin Affect Folate Levels?

Dapagliflozin does not appear to directly deplete circulating folate. SGLT2 inhibitors work by blocking glucose reabsorption in the renal proximal tubule (segment S1), excreting approximately 60 to 80 grams of glucose per day in the urine [3]. This glucosuric mechanism does not extend to water-soluble vitamins such as folate.

Renal Folate Handling

The kidney filters and reabsorbs folate through a separate set of transporters, including folate receptors alpha and beta on the apical brush border membrane of proximal tubule cells. SGLT2 inhibition does not disrupt these folate-specific reabsorption mechanisms. No trial within the Farxiga clinical development program, including DECLARE-TIMI 58 (N=17,160) or DAPA-HF (N=4,744), reported folate depletion as an adverse event [4, 5].

Mild Osmotic Diuresis and Micronutrient Loss

Dapagliflozin does produce a modest diuretic effect through osmotic glucosuria and a secondary natriuretic effect. Clinicians occasionally ask whether this diuresis could wash out water-soluble vitamins. The magnitude of fluid loss from dapagliflozin is smaller than that seen with loop diuretics such as furosemide, and loop diuretics themselves carry only a theoretical, not well-documented, risk of folate depletion. For most patients on dapagliflozin, dietary folate intake through fortified foods provides sufficient daily intake without supplementation [6].

Who Should Pay Attention to Folate When Taking Farxiga?

Certain patient groups have independent reasons to monitor or optimize folate status while on dapagliflozin. The overlap is not about a direct interaction; it reflects shared cardiovascular and renal risk factors.

Patients with MTHFR Variants

Roughly 10 to 15% of people of Northern European ancestry carry the homozygous MTHFR C677T variant (TT genotype), which reduces MTHFR enzyme activity by approximately 70% compared to the wild-type CC genotype [7]. These individuals convert folic acid to active 5-MTHF less efficiently and may accumulate unmetabolized folic acid in plasma. For MTHFR TT patients, supplementing with L-methylfolate (5-MTHF) rather than standard folic acid may produce better increases in plasma 5-MTHF and more significant reductions in homocysteine [7].

Elevated homocysteine is an independent risk marker for cardiovascular and chronic kidney disease progression, both of which are primary indications for dapagliflozin use. A 2022 meta-analysis (N=8,234 participants across 14 randomized controlled trials) found that folic acid supplementation reduced plasma homocysteine by a mean of 3.5 µmol/L (95% CI: 2.8 to 4.2 µmol/L), an effect that was attenuated in MTHFR TT carriers receiving standard folic acid versus active 5-MTHF [8].

Patients with Diabetic Nephropathy

Folate is filtered by the glomerulus and reabsorbed by folate receptors in the proximal tubule. In progressive CKD, glomerular filtration declines and tubular folate handling can become impaired. Patients with eGFR between 25 to 75 mL/min/1.73 m², a range in which dapagliflozin is approved and actively studied per the DAPA-CKD trial (N=4,304), may have lower circulating 5-MTHF [9]. Checking serum folate and homocysteine at baseline is reasonable in this group.

Patients on Metformin

Many people taking Farxiga also take metformin. Metformin reduces serum vitamin B12 by an estimated 19 to 30% over 3.2 years of use, as demonstrated in the long-term arm of the Diabetes Prevention Program Outcomes Study (DPPOS) [10]. Lower B12 impairs the conversion of homocysteine to methionine, effectively creating a functional folate insufficiency even when measured serum folate appears normal. Patients combining dapagliflozin, metformin, and standard folic acid supplementation should have serum B12 and homocysteine checked annually.

Patients Planning Pregnancy

The FDA label for Farxiga advises discontinuing the drug during the second and third trimesters of pregnancy due to adverse effects on fetal renal development [1]. Any woman of childbearing age on Farxiga who is planning conception should also be taking 400 to 800 mcg of folate daily to reduce neural tube defect risk, per U.S. Preventive Services Task Force (USPSTF) recommendations [11]. This is not an interaction concern; it is standard preconception care that coincides with dapagliflozin use.

Pharmacodynamic Considerations: Do Folate and Dapagliflozin Share Any Overlapping Effects?

This is where the combination becomes clinically interesting rather than simply neutral. Dapagliflozin and folate may independently support endothelial function through separate mechanisms, and that overlap is worth understanding.

Dapagliflozin's Vascular Effects

The DECLARE-TIMI 58 trial (N=17,160, median follow-up 4.2 years) showed dapagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 17% versus placebo (HR 0.83; 95% CI: 0.73 to 0.95; P=0.005) [4]. Proposed mechanisms include reduced oxidative stress, natriuresis-mediated preload reduction, and direct cardiac metabolic effects. Dapagliflozin does not lower homocysteine.

Folate's Vascular Effects

Folate is required for the remethylation of homocysteine to methionine. Adequate 5-MTHF also serves as a cofactor for endothelial nitric oxide synthase (eNOS), supporting nitric oxide production independently of homocysteine lowering. A randomized crossover trial published in Circulation (N=41 patients with coronary artery disease) showed that 5 mg/day folic acid for 6 weeks improved brachial artery flow-mediated dilation by 1.1 percentage points (P<0.01), consistent with direct eNOS coupling effects [12].

Combined Endothelial Support

The following clinical decision framework organizes when to simply continue standard folate versus upgrading to methylfolate versus adding monitoring when dapagliflozin is co-prescribed:

| Patient Profile | Recommended Folate Form | Dose | Monitoring | |---|---|---|---| | No MTHFR variant, eGFR >75, no metformin | Folic acid | 400 to 800 mcg/day | Routine | | MTHFR C677T or A1298C heterozygous | L-methylfolate (5-MTHF) | 400 to 1,000 mcg/day | Homocysteine at baseline and 6 months | | MTHFR C677T homozygous (TT) | L-methylfolate (5-MTHF) | 1,000 to 5,000 mcg/day | Homocysteine, B12, serum folate every 6 months | | eGFR 25 to 75 (DAPA-CKD range) | L-methylfolate preferred | 800 mcg/day | Serum folate, homocysteine, B12 annually | | Metformin co-administration | Folic acid + B12 | 400 to 800 mcg folate + 1,000 mcg B12 | B12, homocysteine annually | | Preconception | Folic acid or methylfolate | 400 to 800 mcg/day minimum | Discuss higher doses with OB if MTHFR+ |

Note: doses above 1 mg/day folic acid should be confirmed with a clinician, as high-dose folic acid can mask B12 deficiency anemia.

What Dose of Folate Is Safe with Farxiga?

The tolerable upper intake level (UL) for folic acid from supplements and fortified foods in adults is 1,000 mcg (1 mg) per day, as set by the National Academies of Sciences, Engineering, and Medicine [13]. This ceiling applies specifically to synthetic folic acid, not to naturally occurring food folates or L-methylfolate, which do not carry the same masking-of-B12-deficiency concern.

Standard Supplementation Range

For general supplementation in adults on dapagliflozin with no MTHFR variant and no therapeutic indication for folate, 400 to 800 mcg of folic acid daily remains appropriate and safe. This dose does not interfere with dapagliflozin metabolism or renal glucose excretion.

Therapeutic Folate Doses

Therapeutic doses of 1 to 5 mg/day folic acid are sometimes prescribed for hyperhomocysteinemia, MTHFR variants, or as adjuncts in renal disease. At these doses, folic acid still does not interact pharmacokinetically with dapagliflozin. However, doses above 1 mg should always be prescribed, not self-selected, because the clinical benefit depends on whether elevated homocysteine is the actual driver of risk in that individual patient.

The VITATOPS trial (N=8,164 patients with recent stroke or TIA) found that B-vitamin supplementation including 2 mg folic acid daily did not significantly reduce the primary composite of stroke, MI, or vascular death over 3.4 years (RR 0.91; 95% CI: 0.82 to 1.00; P=0.06), suggesting folate benefits on vascular endpoints are most apparent in populations with documented hyperhomocysteinemia or folate insufficiency rather than unselected patients [14].

Timing: When Should You Take Folate Relative to Farxiga?

No dose-separation window is required. Farxiga can be taken in the morning with or without food, and folate supplements can be taken at any time of day without clinically significant interaction.

Practical Scheduling

Dapagliflozin reaches peak plasma concentration at 1 to 2 hours post-dose. Because no transporter competition or metabolic interaction exists between dapagliflozin and folate, simultaneous ingestion does not reduce efficacy of either compound. Taking both with breakfast is a common patient-friendly approach that improves adherence to both agents.

Food Effects

Folic acid absorption is not meaningfully reduced by food. Dapagliflozin's bioavailability is likewise not significantly altered by a high-fat meal; the FDA label notes a 50% reduction in Cmax with a high-fat meal, but AUC is unaffected, meaning overall drug exposure is preserved [1]. Co-administration with food is acceptable for both.

Monitoring Recommendations

Patients combining folate supplementation with dapagliflozin do not need special monitoring beyond what is already standard for each agent individually, with two exceptions.

Baseline Labs to Consider

For patients newly starting folate supplementation while on dapagliflozin, a baseline serum folate and plasma homocysteine level gives the clinician a reference point. If homocysteine is above 15 µmol/L at baseline, that independently supports optimizing folate form and dose, and also prompts checking B12 and renal function.

The American Diabetes Association (ADA) 2024 Standards of Care recommend annual monitoring of renal function (serum creatinine, eGFR, urine albumin-to-creatinine ratio) in all patients on SGLT2 inhibitors [15]. These same lab draws can include serum B12 and folate at minimal added cost for patients on metformin co-therapy.

When to Flag to Your Prescriber

Contact your prescribing clinician if you develop new neurological symptoms (tingling, cognitive changes) while taking high-dose folic acid with metformin, as this pattern may indicate masked B12 deficiency neuropathy. Folic acid supplementation can normalize macrocytic anemia from B12 deficiency while allowing subacute combined degeneration of the spinal cord to progress silently [16].

What Do the Guidelines Say?

The Farxiga FDA label does not list folate or folic acid as contraindicated, cautioned, or interacting supplements [1]. No SGLT2 inhibitor guideline from the American Diabetes Association, the American College of Cardiology, or the KDIGO 2022 CKD guidelines lists folate as a drug of concern with this class [15, 17].

The USPSTF recommends daily folic acid supplementation of 0.4 to 0.8 mg for all people planning or capable of pregnancy, regardless of concurrent medications, unless specifically contraindicated [11]. This recommendation applies unchanged to people on dapagliflozin.

"All women who are planning a pregnancy or who are capable of becoming pregnant should be advised to take a supplement containing folic acid," states the USPSTF 2023 recommendation statement on folic acid supplementation for the prevention of neural tube defects [11].

The ADA 2024 Standards of Care note that "SGLT2 inhibitors have proven cardiovascular and kidney benefits and should be prioritized in patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD," without restriction based on B-vitamin supplementation status [15].

Practical Steps If You Are Already Taking Both

If you are already taking folate alongside dapagliflozin, you do not need to stop either agent. The combination is pharmacokinetically safe based on available evidence.

Confirm Your Folate Form

Check whether your supplement contains folic acid (the synthetic oxidized form), folinic acid (5-formyl-THF), or L-methylfolate (5-MTHF). If you have a known MTHFR variant, switching from folic acid to a 400 to 1,000 mcg L-methylfolate supplement may produce better plasma 5-MTHF levels and more effective homocysteine reduction [7].

Review Your Full Supplement Stack

People managing type 2 diabetes, heart failure, or CKD often take multiple supplements. Berberine, CoQ10, magnesium, and vitamin D are common additions. None of these are expected to interact with dapagliflozin's UGT1A9 metabolism or with folate absorption, but reviewing the full stack with a clinician at least annually is prudent.

Check eGFR Trajectory

Because dapagliflozin slows eGFR decline in CKD, the DAPA-CKD trial showed a 44% relative risk reduction in sustained 50% eGFR decline, end-stage kidney disease, or renal or cardiovascular death (HR 0.56; 95% CI: 0.45 to 0.68; P<0.001) [9]. Preserving kidney function also preserves tubular folate reabsorption over time, making dapagliflozin therapy itself indirectly supportive of adequate folate status in CKD patients.